Elicio Therapeutics (ELTX) Assets Average (2021 - 2026)

Elicio Therapeutics has reported Assets Average for 6 years, with the latest figure at $24.3 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average fell 13.85% year-over-year to $24.3 million; the trailing twelve-month figure through Mar 2026 stood at $24.3 million (down 13.85% YoY), and the FY2025 full-year result was $27.0 million, down 2.32% from the prior year.
• Assets Average for Q1 2026 stood at $24.3 million, down from $27.1 million in the prior quarter.
• The five-year high for Assets Average was $88.9 million in Q1 2022, with the low at $20.1 million in Q2 2024.
• Historically, Assets Average has averaged $38.3 million across 5 years, with a median of $29.1 million in 2023.
• Annual changes were most pronounced in 2023 — Assets Average tumbled 63.76% — and 2025, when it surged 43.44%.
• Elicio Therapeutics' Assets Average stood at $42.0 million in 2022, then slumped by 30.78% to $29.1 million in 2023, then gained by 14.51% to $33.3 million in 2024, then retreated by 18.66% to $27.1 million in 2025, then dropped by 10.33% to $24.3 million in 2026.
• The last three Assets Average figures came in at $24.3 million (Q1 2026), $27.1 million (Q4 2025), and $28.9 million (Q3 2025), per Business Quant data.